Physician profile
Thomas Moore Davis
NPI 1053402164
$2,957.32
in general payments reported to CMS, 2019-2025
16 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $159 · 2021: $880 · 2022: $678 · 2023: $465 · 2024: $143 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,230.94 | 2019-2025 | Clareon, Precision 1 |
| New World Medical,INC. | $657.88 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Johnson & Johnson Surgical Vision, INC. | $202.03 | 2021-2024 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $193.93 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $152.46 | 2019-2020 | |
| Allergan, INC. | $135.27 | 2020-2022 | |
| Astellas Pharma US INC | $84.50 | 2023 | |
| Ocular Therapeutix, INC. | $68.59 | 2020-2023 | Dextenza |
| Glaukos Corporation | $50.04 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $47.85 | 2022-2023 | Infuse |
| Abbvie INC. | $43.94 | 2022 | |
| Aerie Pharmaceuticals, INC. | $20.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.47 | 2019 | |
| Oyster Point Pharma, INC. | $17.44 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $16.20 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.